I think it was probably me who mistakenly said some things about the PD1 trial that are incorrect. Here is the correction: this study provides a 2:1 chance to receive MK3475 (not 3:1). This study is not being amended to remove the chemo option; it remains randomized to chemo with potential for crossover.
PN001 (different study) has been amended to open additional slots and is not randomized to anything other than MK3475. This will affect all sites that are participating in this study. Those sites are listed on clinicaltrials.gov.
Yes, this is the MK3475, probably is not posted yet on the govt. site. This will be an amendment. Does that answer your question? It is always best to call the individual site and speak with the research coordinator to make sure of particulars..
This confusing to everyone, so no problem. It is one person designated to chemo agent (choice of three I believe between you and doctor) vs. 2 randomized to PD1. If the patient progresses on the chemo, they can cross over to the PD1.